Scholarlink

<p>Vasculitis associated with anti-neutrophil cytoplasmic antibodies (ANCA) is a rare disease with a potentially severe course. Affected patients should be diagnosed as quickly as possible and given suitable treatment according to the current study situation. Considerable progress has been made in the treatment of this disease in recent years, so that a largely evidence-based therapy with immunosuppressants and biologics is now possible. The guideline on the diagnosis and treatment of ANCA-associated vasculitis was raised from S1 level (2017) to S3 level. This guideline is the first German guideline on the diagnosis and treatment of ANCA-associated vasculitis at S3 level.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden

  • 期刊论文

  • 发表日期：

    2025年4月2日

查看全文
  • J. U. Holle,
  • T. Kubacki,
  • P. Aries,
  • B. Hellmich,
  • A. Kernder,
  • C. Kneitz,
  • P. Lamprecht,
  • J. H. Schirmer,
  • A. Schreiber,
  • P. Berlit,
  • T. A. Bley,
  • S. Blödt,
  • L. Decker,
  • K. de Groot,
  • S. Engel,
  • I. Jordans,
  • B. Frye,
  • M. Haubitz,
  • K. Holl-Ulrich,
  • I. Kötter,
  • M. Laudien,
  • K. Milger-Kneidinger,
  • C. Muche-Borowski,
  • U. Müller-Ladner,
  • T. Neß,
  • B. Nölle,
  • E. Reinhold-Keller,
  • N. Ruffer,
  • K. Scheuermann,
  • N. Venhoff,
  • S. von Vietinghoff,
  • T. Wiech,
  • M. Zänker,
  • F. Moosig

摘要

Vasculitis associated with anti-neutrophil cytoplasmic antibodies (ANCA) is a rare disease with a potentially severe course. Affected patients should be diagnosed as quickly as possible and given suitable treatment according to the current study situation. Considerable progress has been made in the treatment of this disease in recent years, so that a largely evidence-based therapy with immunosuppressants and biologics is now possible. The guideline on the diagnosis and treatment of ANCA-associated vasculitis was raised from S1 level (2017) to S3 level. This guideline is the first German guideline on the diagnosis and treatment of ANCA-associated vasculitis at S3 level.